Hepion Pharmaceuticals

$1.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.60 (-27.52%) Today
+$0.06 (+3.80%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell HEPA and other stocks, options, and ETFs commission-free!

About HEPA

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ. The listed name for HEPA is Hepion Pharmaceuticals, Inc. Common Stock.

CEO
Robert T. Foster
Employees
12
Headquarters
Edison, New Jersey
Founded
2013
Market Cap
14.26M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.32M
High Today
$1.65
Low Today
$1.51
Open Price
$1.58
Volume
10.50M
52 Week High
$8.35
52 Week Low
$1.00

Collections

HEPA Earnings

-$7.48
-$4.99
-$2.49
$0.00
Q4 FY18
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
-$0.69 per share

You May Also Like